✦ LIBER ✦

A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors

✍ Scribed by Karp, D.D; Ferrante, K.J; Tensfeldt, T.G; Thurer, R.L; LoCicero, J; Huberman, M.S; Wirth, F; Hellman, R; Poulin, P; Silberman, S.L; Redifer, P; Allen, L.F; Posner, M; Schnipper, L.E

Book ID: 118569753
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 111 KB
Volume: 29
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(00)80208-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I, pharmacokinetic (PK) and biolog

Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin in patients with advanced solid malignancies

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Phase I, pharmacokinetic (PK), and biolo

Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 (Erlotinib or Tarceva) in combination with docetaxel

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Phase I dose escalation study of MK-0457

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

✍ Anne M. Traynor; Maureen Hewitt; Glenn Liu; Keith T. Flaherty; Jason Clark; Stev 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 252 KB

Phase I dose-finding and pharmacokinetic

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

✍ Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Sh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

A phase I dose escalation study of BIBW

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

✍ Eskens, F A L M; Mom, C H; Planting, A S T; Gietema, J A; Amelsberg, A; Huisman, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 173 KB

Phase I Pharmacokinetic and Pharmacodyna

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

✍ Paz-Ares, L. G.; Gomez-Roca, C.; Delord, J.-P.; Cervantes, A.; Markman, B.; Corr 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 192 KB